Table 1 Population characteristics
|  | Overall (n = 224) | CMET+ (n = 112) | CMET- Controls (n = 112) | pb |
|---|---|---|---|---|
Clinical characteristics | ||||
 Age (years) | 58 ± 17 | 57 ± 16 | 58 ± 18 | 0.68 |
 Gender (male) | 59% (133) | 63% (71) | 55% (62) | 0.23 |
 Body surface area (kg/m2)a | 1.9 ± 0.3 | 1.9 ± 0.3 | 1.9 ± 0.3 | 0.55 |
 Cancer etiologiesb |  |  |  |  |
  Sarcoma | 20% (44) | 20% (22) | 20% (22) | – |
  Lung | 16% (36) | 16% (18) | 16% (18) | – |
  Genitourinary | 15% (34) | 15% (17) | 15% (17) | – |
  Gastrointestinal | 13% (28) | 13% (14) | 14% (14) | – |
  Skin/melanoma | 13% (28) | 13% (14) | 13% (14) | – |
  Lymphoma | 8% (18) | 8% (9) | 8% (9) | – |
  Endocrine | 8% (18) | 8% (9) | 8% (9) | – |
Anti-cancer regimen | Â | Â | Â | Â |
 Chemotherapy |  |  |  |  |
  Alkylating agent | 44% (99) | 46% (52) | 41% (46) | 0.47 |
  Plant alkaloid | 31% (70) | 32% (36) | 30% (34) | 0.88 |
  Antitumor antibiotics | 21% (48) | 21% (23) | 23% (26) | 0.69 |
  Antimetabolites | 31% (70) | 35% (39) | 27% (30) | 0.19 |
  Topoisomerase inhibitors | 8% (17) | 7% (8) | 8% (9) | 1.00 |
  Anthracycline | 21% (46) | 19% (21) | 23% (26) | 0.41 |
 Monoclonal antibodies |  |  |  |  |
  Tyrosine kinase inhibitors | 23% (51) | 20% (22) | 28% (31) | 0.21 |
  Other kinase inhibitors | 4% (8) | 2% (2) | 6% (7) | 0.18 |
  Immunotherapy | 21% (47) | 21% (24) | 20% (22) | 0.84 |
 Radiation therapy |  |  |  |  |
  Mediastinal radiation | 13% (28) | 18% (20) | 7% (8) | 0.01 |
  Other radiation | 38% (84) | 40% (45) | 35% (39) | 0.49 |
Anticoagulation therapy | Â | Â | Â | Â |
 Overall | 22% (50) | 28% (31) | 17% (19) | 0.07 |
  Low molecular weight heparin | 24% (53) | 32% (36) | 16% (18) | 0.01 |
  Warfarin | 3% (6) | 4% (4) | 2% (2) | 0.69 |
  Direct Oral Anticoagulant | 15% (34) | 18% (20) | 13% (14) | 0.26 |
Cardiovascular disease risk factors |  |  |  |  |
 Hypertension | 43% (97) | 41% (46) | 45% (51) | 0.59 |
 Hyperlipidemia | 31% (69) | 28% (31) | 34% (38) | 0.35 |
 Diabetes mellitus | 14% (31) | 11% (12) | 17% (19) | 0.23 |
 Smoking | 38% (79) | 31% (35) | 39% (44) | 0.26 |
Cardiopulmonary disease | Â | Â | Â | Â |
 Coronary artery disease | 11% (24) | 11% (12) | 11% (12) | 1.00 |
 Atrial fibrillation/flutter | 16% (35) | 13% (14) | 19% (21) | 0.27 |
 Pulmonary disease | 6% (13) | 3% (3) | 9% (10) | 0.09 |
 Pulmonary hypertension | 16% (36) | 13% (14) | 20% (22) | 0.17 |
Cardiac morphology and function | ||||
 Left ventricle |  |  |  |  |
  Ejection fraction (%) | 61 ± 11 | 63 ± 8 | 59 ± 12 | 0.004 |
  End-diastolic volume (mL) | 124 ± 41 | 114 ± 34 | 131 ± 43 | 0.002 |
  End-systolic volume (mL) | 51 ± 29 | 42 ± 17 | 57 ± 32 |  < 0.001 |
  Stroke volume (mL) | 73 ± 21 | 72 ± 22 | 75 ± 21 | 0.38 |
  Myocardial mass (gm) | 118 ± 49 | 117 ± 55 | 116 ± 37 | 0.83 |
 Right ventricle |  |  |  |  |
  Ejection fraction (%) | 54 ± 9 | 54 ± 9 | 53 ± 8 | 0.30 |
  End-diastolic volume (mL) | 135 ± 44 | 130 ± 37 | 141 ± 50 | 0.08 |
  End-systolic volume (mL) | 64 ± 29 | 60 ± 24 | 69 ± 32 | 0.03 |
  Stroke volume (mL) | 70 ± 23 | 70 ± 23 | 72 ± 23 | 0.44 |
 Atria |  |  |  |  |
  Left atrial area (cm2) | 20 ± 6 | 19 ± 5 | 21 ± 7 | 0.02 |
  Right atrial area (cm2) | 19 ± 6 | 19 ± 6 | 19 ± 6 | 0.98 |
 Pericardial effusion | 24% (53) | 30% (33) | 19% (21) | 0.07 |